Abstract
Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective: To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Results: Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions: Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1284-1293 |
| Number of pages | 10 |
| Journal | Allergy: European Journal of Allergy and Clinical Immunology |
| Volume | 73 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jun 1 2018 |
Fingerprint
Keywords
- atopic dermatitis
- epidemiology
- prevalence
- severity
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Epidemiology of atopic dermatitis in adults : Results from an international survey. / Barbarot, S.; Auziere, S.; Gadkari, A.; Girolomoni, G.; Puig, L.; Simpson, Eric; Margolis, D. J.; de Bruin-Weller, M.; Eckert, L.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 6, 01.06.2018, p. 1284-1293.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Epidemiology of atopic dermatitis in adults
T2 - Results from an international survey
AU - Barbarot, S.
AU - Auziere, S.
AU - Gadkari, A.
AU - Girolomoni, G.
AU - Puig, L.
AU - Simpson, Eric
AU - Margolis, D. J.
AU - de Bruin-Weller, M.
AU - Eckert, L.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective: To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Results: Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions: Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
AB - Background: There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). Objective: To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Results: Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Conclusions: Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.
KW - atopic dermatitis
KW - epidemiology
KW - prevalence
KW - severity
UR - http://www.scopus.com/inward/record.url?scp=85041896926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041896926&partnerID=8YFLogxK
U2 - 10.1111/all.13401
DO - 10.1111/all.13401
M3 - Article
C2 - 29319189
AN - SCOPUS:85041896926
VL - 73
SP - 1284
EP - 1293
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0108-1675
IS - 6
ER -